L26/P-908 Ovarian regeneration with umbilical cord mesenchymal stem cells: preclinical evidence and phase 1 clinical trial in premature ovarian insufficiency
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von J.E. Lee und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Can human umbilical cord mesenchymal stem cells (hUC-MSCs) safely restore ovarian function in premature ovarian insufficiency (POI) patients, and what are the underlying cellular mechanisms? Summary answer Phase 1 trial demonstrated acceptable safety with significant FSH reduction and menstrual resumption; preclinical studies showed 77% follicle restoration through epithelial wound-healing mechanisms. What is known already Premature ovarian insufficiency affects 1-2% of women under 40 with limited therapeutic options beyond hormone replacement therapy, which does not restore fertility. While preclinical mouse studies demonstrate mesenchymal stem cell regenerative potential in chemotherapy-induced ovarian injury models, controlled clinical trials in human POI patients are extremely scarce, with only small uncontrolled case series reported, and the underlying cellular mechanisms remain poorly characterized. Study design, size, duration This study comprised preclinical and clinical phases. Preclinical: Female ICR mice (n = 10/group, 5 groups) received cyclophosphamide-induced ovarian injury followed by dose-escalating hUC-MSCs (low: 5.33 × 104, moderate: 8 × 104, high: 1.07 × 10⁵ cells/mouse) with 28-day observation and single-cell RNA sequencing. Phase 1 clinical trial: Single-center, open-label trial enrolled six POI patients receiving single intravenous hUC-MSC infusion (1.6 × 10⁸ cells) with 24-week safety and efficacy monitoring using 3 + 3 dose-escalation design. Participants/materials, setting, methods Preclinical: Female ICR mice received GMP-manufactured hUC-MSCs from umbilical cord Wharton’s jelly. Assessments included histological analysis with follicle counting, TUNEL apoptosis assay, AMH immunostaining, in vitro fertilization outcomes, and single-cell RNA sequencing with CellChat analysis. Clinical: Six POI patients (age 25-40, amenorrhea ≥4 months, FSH >40 mIU/mL) received intravenous hUC-MSCs at a single center. Safety monitoring included adverse events and laboratory tests; efficacy assessments included FSH, AMH, estradiol, antral follicle count, and menstrual resumption. Main results and the role of chance Preclinical studies demonstrated dose-dependent ovarian restoration. Compared to cyclophosphamide-injured controls, high-dose hUC-MSCs significantly increased total follicle count by 34% and primordial follicles by 77% (p < 0.001). TUNEL-positive apoptotic area decreased from 17% to 9% (p < 0.01), and AMH expression recovered significantly (H-score: 1.0 vs 1.9, p < 0.01). In vitro fertilization outcomes showed remarkable improvement, with high-dose treatment achieving 73.4% fertilization and 73.9% blastocyst development rates compared to 29.6% and 29.2% in injured controls. Single-cell RNA sequencing revealed upregulation of wound-healing genes (Col3a1, Col1a2) in ovarian epithelial cells, with enhanced intercellular communication through Angptl4-Sdc and collagen family signaling pathways promoting vascular regeneration via stromal cells. In the phase 1 clinical trial, hUC-MSCs demonstrated acceptable safety with no serious adverse events. Exploratory efficacy analysis showed statistically significant FSH reduction at week 24 (baseline: 82.96±46.27 vs week 24: 75.48±37.88 mIU/mL, p = 0.0288). Individual patients demonstrated transient estradiol elevations exceeding 100 pg/mL, emergence of antral follicles (mean 17.31±21.23% at week 24), and one patient (16.7%) experienced spontaneous menstrual resumption after six years of amenorrhea. Limitations, reasons for caution The phase 1 trial’s small sample size (n = 6), lack of control group, and 24-week follow-up limit efficacy conclusions. High inter-patient variability and single dose evaluation warrant larger controlled trials. The cyclophosphamide mouse model incompletely represents primary POI heterogeneity. Wider implications of the findings These findings advance stem cell therapy from preclinical promise to clinical reality for POI treatment. Novel mechanistic insights enable biomarker development for patient selection. The acceptable safety profile and biological activity signals justify larger randomized controlled trials evaluating reproductive outcomes, potentially offering fertility restoration beyond current palliative approaches. Trial registration number Yes
Zitieren
APA
Lee, J., & Kim, J. (2026). L26/P-908 Ovarian regeneration with umbilical cord mesenchymal stem cells: preclinical evidence and phase 1 clinical trial in premature ovarian insufficiency. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1232
Vancouver
Lee J, Kim J. L26/P-908 Ovarian regeneration with umbilical cord mesenchymal stem cells: preclinical evidence and phase 1 clinical trial in premature ovarian insufficiency. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1232
BibTeX
@article{Lee2026,
author = {Lee, J.E. and Kim, J.H.},
title = {L26/P-908 Ovarian regeneration with umbilical cord mesenchymal stem cells: preclinical evidence and phase 1 clinical trial in premature ovarian insufficiency},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1232}
}
EUVIMED